AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program
AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories
AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories